These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Fentanyl Family at the Mu-Opioid Receptor: Uniform Assessment of Binding and Computational Analysis. Lipiński PFJ; Kosson P; Matalińska J; Roszkowski P; Czarnocki Z; Jarończyk M; Misicka A; Dobrowolski JC; Sadlej J Molecules; 2019 Feb; 24(4):. PubMed ID: 30791394 [TBL] [Abstract][Full Text] [Related]
4. Structural basis of μ-opioid receptor targeting by a nanobody antagonist. Yu J; Kumar A; Zhang X; Martin C; Van Holsbeeck K; Raia P; Koehl A; Laeremans T; Steyaert J; Manglik A; Ballet S; Boland A; Stoeber M Nat Commun; 2024 Oct; 15(1):8687. PubMed ID: 39384768 [TBL] [Abstract][Full Text] [Related]
5. Mutation of human mu opioid receptor extracellular "disulfide cysteine" residues alters ligand binding but does not prevent receptor targeting to the cell plasma membrane. Zhang P; Johnson PS; Zöllner C; Wang W; Wang Z; Montes AE; Seidleck BK; Blaschak CJ; Surratt CK Brain Res Mol Brain Res; 1999 Oct; 72(2):195-204. PubMed ID: 10529478 [TBL] [Abstract][Full Text] [Related]
6. Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor. Subramanian G; Paterlini MG; Portoghese PS; Ferguson DM J Med Chem; 2000 Feb; 43(3):381-91. PubMed ID: 10669565 [TBL] [Abstract][Full Text] [Related]
7. Molecular dynamics of fentanyl bound to μ-opioid receptor. Lipiński PFJ; Jarończyk M; Dobrowolski JC; Sadlej J J Mol Model; 2019 May; 25(5):144. PubMed ID: 31053968 [TBL] [Abstract][Full Text] [Related]
8. Modulation of μ-opioid receptor activation by acidic pH is dependent on ligand structure and an ionizable amino acid residue. Meyer J; Del Vecchio G; Seitz V; Massaly N; Stein C Br J Pharmacol; 2019 Dec; 176(23):4510-4520. PubMed ID: 31355457 [TBL] [Abstract][Full Text] [Related]
9. Molecular recognition of morphine and fentanyl by the human μ-opioid receptor. Zhuang Y; Wang Y; He B; He X; Zhou XE; Guo S; Rao Q; Yang J; Liu J; Zhou Q; Wang X; Liu M; Liu W; Jiang X; Yang D; Jiang H; Shen J; Melcher K; Chen H; Jiang Y; Cheng X; Wang MW; Xie X; Xu HE Cell; 2022 Nov; 185(23):4361-4375.e19. PubMed ID: 36368306 [TBL] [Abstract][Full Text] [Related]
10. Structural Basis of μ-Opioid Receptor-Targeting by a Nanobody Antagonist. Yu J; Kumar A; Zhang X; Martin C; Raia P; Koehl A; Laeremans T; Steyaert J; Manglik A; Ballet S; Boland A; Stoeber M bioRxiv; 2023 Dec; ():. PubMed ID: 38106026 [TBL] [Abstract][Full Text] [Related]
11. Opioid peptide receptor studies, 11: involvement of Tyr148, Trp318 and His319 of the rat mu-opioid receptor in binding of mu-selective ligands. Xu H; Lu YF; Partilla JS; Zheng QX; Wang JB; Brine GA; Carroll FI; Rice KC; Chen KX; Chi ZQ; Rothman RB Synapse; 1999 Apr; 32(1):23-8. PubMed ID: 10188634 [TBL] [Abstract][Full Text] [Related]
12. Ligand-induced μ opioid receptor internalization in enteric neurons following chronic treatment with the opiate fentanyl. Anselmi L; Jaramillo I; Palacios M; Huynh J; Sternini C J Neurosci Res; 2013 Jun; 91(6):854-60. PubMed ID: 23553842 [TBL] [Abstract][Full Text] [Related]
13. Strategies and considerations of G-protein-coupled receptor photopharmacology. Berizzi AE; Goudet C Adv Pharmacol; 2020; 88():143-172. PubMed ID: 32416866 [TBL] [Abstract][Full Text] [Related]
14. Structural Assessment of Agonist Efficacy in the μ-Opioid Receptor: Morphine and Fentanyl Elicit Different Activation Patterns. Ricarte A; Dalton JAR; Giraldo J J Chem Inf Model; 2021 Mar; 61(3):1251-1274. PubMed ID: 33448226 [TBL] [Abstract][Full Text] [Related]
15. Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonists. Zaidi SA; Arnatt CK; He H; Selley DE; Mosier PD; Kellogg GE; Zhang Y Bioorg Med Chem; 2013 Nov; 21(21):6405-13. PubMed ID: 24055076 [TBL] [Abstract][Full Text] [Related]
16. A photochromic agonist for μ-opioid receptors. Schönberger M; Trauner D Angew Chem Int Ed Engl; 2014 Mar; 53(12):3264-7. PubMed ID: 24519993 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites. Dardonville C; Fernandez-Fernandez C; Gibbons SL; Ryan GJ; Jagerovic N; Gabilondo AM; Meana JJ; Callado LF Bioorg Med Chem; 2006 Oct; 14(19):6570-80. PubMed ID: 16797997 [TBL] [Abstract][Full Text] [Related]
18. Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain. Podolsky AT; Sandweiss A; Hu J; Bilsky EJ; Cain JP; Kumirov VK; Lee YS; Hruby VJ; Vardanyan RS; Vanderah TW Life Sci; 2013 Dec; 93(25-26):1010-6. PubMed ID: 24084045 [TBL] [Abstract][Full Text] [Related]
19. Opioid peptide receptor studies. 7. The methylfentanyl congener RTI-4614-4 and its four enantiomers bind to different domains of the rat mu opioid receptor. Lu YF; Xu H; Liu-Chen LY; Chen C; Partilla JS; Brine GA; Carroll FI; Rice KC; Lai J; Porreca F; Sadee W; Rothman RB Synapse; 1998 Feb; 28(2):117-24. PubMed ID: 9450512 [TBL] [Abstract][Full Text] [Related]
20. Ligand recognition in mu opioid receptor: experimentally based modeling of mu opioid receptor binding sites and their testing by ligand docking. Sagara T; Egashira H; Okamura M; Fujii I; Shimohigashi Y; Kanematsu K Bioorg Med Chem; 1996 Dec; 4(12):2151-66. PubMed ID: 9022978 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]